Archive for May, 2011

Adalimumab goes beyond degenerative bone disease, sustains clinical remission after 2 years of therapy in Crohn’s disease

Friday, May 27th, 2011

AdalimumabJoint pains have inflicted thousands of people worldwide. Age is a non-modifiable risk factor when it comes to degenerative bone disease. However, certain autoimmune joint diseases affect the young population as well. Juvenile idiopathic arthritis, ankylosing spondylitis, rheumatoid arthritis and psoriatic arthritis are just a few of the autoimmune joint diseases that affect people from all age groups. A naturally occurring cytokine, TNF-α causes our immune system to “overreact” with the ultimate goal of protecting our bodies from harmful agents but the aftermath of the battle leaves an undesirable trail mostly attributed to inflammation in virtually any part of the human body.

With TNF-α overproduction having several undesirable effects, studies on TNF-α blockade are wide and extensive. One of the most promising results of these studies produced the injectable protein, Adalimumab (Humira). In 2008, Adalimumab became the first fully human monoclonal antibody drug approved by the FDA for the treatment of degenerative joint diseases.

Recently, Adalimumab was put in the spotlight again for yielding positive clinical outcomes for the long term treatment of Crohn’s disease. A randomized double blind study conducted by R. Panaccione et al over a period of two years saw continued progress on the Inflammatory Bowel Disease Questionnaire completed by the participants. Parameter improvements were most apparent in the quality of life and reduced number of hospitalizations during the two year treatment period with 40 mg Adalimumab every other week.

With newer treatment modalities surfacing, issues with efficacy and safety of new drugs or old drugs with new indications, the pharmaceutical community recognizes the need for continuing the research work already started. As a member of this elite enterprise, LGM Pharma supplies Adalimumab CAS# 331731-18-1 and other Monoclonal Antibodies to global pharmaceutical companies involved in their R & D studies. Product quality, company reliability, and quality customer service sits on LGM Pharma’s core priorities.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

LGM Pharma responds to soaring Potassium Iodide demands in the US amidst fears of radiation contamination in Japan and West Coast

Tuesday, May 17th, 2011
Fukushima-daiichi

Photograph courtesy Tokyo Electric Power Company via Kyodo/AP

For several years now, LGM Pharma has been a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged a longstanding partnership with GlaxoSmithKline, Eli Lilly and Merck, just to name a few of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients. Among these is Potassium Iodide CAS# 7681-11-0.

The latest national earthquake and consequent nuclear reactor leaks in Japan brought potassium iodide sales to the ceiling. From Fukushima, Japan to Los Angeles, USA, concerned residents wasted no time in grabbing their own supply of potassium iodide which is available in the U.S. as over the counter (OTC) pills.  The pills are available as 65 mg and 130 mg doses for child and adult, respectively. These pills have been shown to exhibit protective thyroid properties by blocking the formation of tumors caused by high radiation levels.

Though unanticipated, the sudden surge in the demand for potassium iodide pills after a nuclear disaster has not been surprising to the medical and pharmaceutical community. The UN Scientific Committee has named thyroid cancer as the Chernobyl nuclear disaster’s biggest negative health impact to the immediate community residents. In its February 2011 report, more than 6,000 residents from Belarus, Ukraine and Russia have been diagnosed with thyroid cancer as of 2006 since acquiring dangerous levels of radiation in their bodies during the time of the incident.

Though the extent of the Fukushima incident is nothing like the Chernobyl disaster, that hasn’t stopped a lot of the West Coast residents from being prepared for the worst. Quick to respond to the world’s health demands is LGM Pharma. The Japan quake has firmly reiterated the company’s commitment to filling in the gaps in the supply chain of the active pharmaceutical ingredient, Potassium Iodide CAS# 7681-11-0 to it’s pharmaceutical clients involved in its research, development and global distribution.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Trastuzumab and Chemo Combo for Advanced Gastroesophageal Junction Cancer

Monday, May 16th, 2011

TrastuzumabA study conducted by the Seoul National University College of Medicine, Seoul in South Korea found that the monoclonal antibody, Trastuzumab (Herceptin) used with chemotherapeutic drugs in the treatment of HER2-positive advanced gastroesophageal junction cancer showed a promising new treatment option for patients. HER2 protein is responsible for cell growth and division and the cell proliferation is regulated at different checkpoints. A defect in this protein may result in the uncontrolled proliferation of the cell resulting in tumour.  Trastuzumab is a humanized monoclonal antibody which help arrest the cell cycle at the G1 phase and hence the cell division. Trastuzumab binds to the HER2/neu receptor and exerts it effect by down regulating the HER2/neu receptor and arresting the cell cycle.

The participants were randomly assigned in a 1:1 ratio to receive a chemotherapy regimen consisting of capecitabine plus cisplatin or fluorouracil plus cisplatin given every 3 weeks for six cycles or chemotherapy in combination with intravenous Trastuzumab. The survival rate of patients on chemotherapy with Trastuzumab was slightly higher than those who were on chemotherapy alone. Additionally, the regimen with Trastuzumab did not increase the adverse effects most commonly associated with chemotherapeutic agents. Nausea and vomiting was not significantly higher in the patients given Trastuzumab than those in chemotherapeutic agents alone.

The propensity of the drug to increase survival rates without the additional adverse effects proves to be a promising breakthrough in gastroesophageal junction cancer research. However, since the results of the study emerged, limited data exists about the optimal duration of Trastuzumab therapy. Fortunately, the pharmaceutical field has not faltered in its quest to continually improve the optimal duration data profile of the drug. In order to facilitate these endeavors, LGM Pharma has made the supply of Trastuzumab CAS# 180288-69-1 to pharmaceutical companies a top priority. Currently, the company works in collaboration with GMP and ISO certified manufacturers in order to meet the growing demands for active pharmaceutical ingredients for research and development purposes.

 

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Levocloperastine Fendizoate: The Better Antitussive Agent Over Codeine

Thursday, May 5th, 2011

sick-chest-xrayMany of the antitussive agents available in the market today act on the CNS, and cause the adverse events mostly associated with them such as sedation, vomiting, and nausea. One in particular, codeine, can lead to drug dependence. Because of this, pharmaceutical companies were prompted to develop a peripherally-acting antitussive agent that minimizes these central adverse effects. The endeavor resulted in a new research molecule, Levocloperastine Fendizoate CAS# 220329-19-1.

What is levocloperastine fendizoate and how does it work?

Levocloperastine is the levorotatory isomer of DL-cloperastine and fendizoate is its salt. Levocloperastine fendizoate is an antitussive agent that acts both centrally, on the bulbar cough center, and peripherally, on the cough receptors in the tracheobronchial tree. This dual mechanism of action makes levocloperastine fendizoate effective in the treatment of cough associated with many chronic and acute conditions in patients of all ages.

Levocloperastine Fendizoate Supply:

LGM Pharma has been supplying this API to various pharmaceutical companies around the globe who are actively involved in its ongoing research. If you are one of those companies looking to source this material for R&D or compounding purposes, inquire with us about purchasing Levocloperastine Fendizoate CAS# 220329-19-1.

Levocloperastine Fendizoate CAS No 220329-19-1

Clinical Studies:

The past clinical studies on levocloperastine fendizoate demonstrated its superior pharmacological effect over other antitussive agents currently used in cough medications. In 1992, a large-scale clinical trial showed the drug’s antitussive activity to be similar to the opiate agent, codeine.

In 2004, a clinical trial was conducted in Italy by Aliprandi et al., using children and adults as study participants. The majority of the children who participated had acute bronchial inflammatory conditions at the time, while adult subjects had chronic pulmonary disorders. The antitussive effects were observed as early as the first day of treatment, manifested by improved subjective, objective, and laboratory parameters. Objective measurements used in the study included reduction in cough frequency and intensity, nighttime disturbances, and difficulties in expectoration. Laboratory measurements included improvements on cardiovascular and respiratory parameters.

The same study found out that levocloperastine fendizoate exhibited a faster onset of action with a substantial reduction in the intensity and frequency of cough. It was also generally well-tolerated by the body. Unlike codeine, it did not produce the adverse effects associated with the opiate agent such as sedation, dry mouth, nausea, and drug dependence.

Moreover, levocloperastine fendizoate didn’t interact with other drugs which makes it a safe alternative for patients who take medications for other conditions. Given the amount of positive research results, it will only be a matter of time before levocloperastine fendizoate joins the market of antitussive agents currently used in medical practice today.

 

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

Vilazodone Gets FDA Approval For Major Depressive Disorder (MDD)

Monday, May 2nd, 2011

vilazodoneVilazodone just received FDA approval for the treatment of major depressive depression (MDD) on January of this year.  The drug will be available in 10 mg, 20 mg and 40 mg dosage forms.

Major Depressive Disorder is commonly known as major depression. Unlike bipolar disorder, it is characterized by one extreme mood i.e. depressed mood. Fatigue, irritability, loss of sleep and appetite are just some of its symptoms. The disorder is not new and is currently treated by antidepressants that act on the serotonin and norepinephrine receptors and the monoamine oxidase enzyme (MAO). Although proven effective and safe, these drugs are not without side effects that seriously undermine a patient’s compliance to therapy. Clinical Data Inc. recently developed the drug, Vilazodone (Viibryd) to address these shortcomings. According to the company, Vilazodone did not cause a body weight change nor altered hepatic and cardiac parameters.

depressionVilazodone is a combination of an SSRI and 5HT1A serotonin receptor partial agonist that has recently gained FDA approval for the treatment of MDD. Although its mechanism of action has not been fully understood yet the researchers at Clinical Data Inc. thought that its pharmacologic action stems from the drug’s ability to enhance serotonergic activity in the patient’s brain. Carol R. Reed, executive vice president of Clinical Data, said that it will provide a new choice for clinicians since the drugs currently used to treat the disorder are known to cause intolerable side effects which accounts for a great percentage of discontinued and unsuccessful drug therapies.

According to the published clinical trials data, Vilazodone is safe and effective compared to placebo. The recommended starting dose is 10 mg in the first week gradually titrated up to 20 mg in the second week and subsequently 40 mg thereafter. Like other antidepressant drugs available in the market, it needs to be gradually tapered before a complete cessation of therapy is achieved.

LGM Pharma is hot on the tracks of this new drug development. Since gaining approval, LGM Pharma has become the preferred supplier of Vilazodone CAS# 163521-12-8 by pharmaceutical companies who are currently engaged in its R&D.

 

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.